This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


User:Ivan E. Wang/Sandbox 1

From Proteopedia

< User:Ivan E. Wang(Difference between revisions)
Jump to: navigation, search
Current revision (16:59, 14 April 2020) (edit) (undo)
 
(16 intermediate revisions not shown.)
Line 1: Line 1:
-
'''Retinal Pigment Epithelium 65 (Retinoid Isomerohydrolase) complex with (''R''/''S'')-emixustat and palmitate'''
+
[[Media:RPE65_with_emixustat.mp4|PLACEHOLDER] width="576" height="324"]
 +
[[/Media:RPE65_with_emixustat.mp4]]
-
<StructureSection load='4rsc' size='340' side='right' caption='Emixustat bound in the active site of RPE65' scene=''>
 
-
Retinal pigment epithelium 65 (RPE65) also known as retinoid isomerohydrolase is a 65 kDa enzyme located within the human retinal pigment epithelium cells responsible for the chemical conversion of ''all-trans''-retinyl ester to ''11-cis''-retinol in the visual cycle.
 
-
</StructureSection>
 
-
= Function =
 
-
== Structural Features of RPE65 ==
 
-
(PLACEHOLDER)
 
-
== Enzymatic Catalyzed Reaction ==
+
[[Media:RPE65_with_emixustat.mp4|PLACEHOLDER]]
-
(PLACEHOLDER)
+
-
[[Image:Visual Cycle.jpg|thumb|left|512 px|alt=Figure 2: Human Visual Cycle| Figure 2: The canonical Visual Cycle in Humans <ref>DOI 10.1016/j.bbadis.2018.04.014</ref>]]
+
-
= Protein-Ligand Interaction =
+
[[Media:RPE65_with_emixustat.mp4]]
-
== Endogenous Ligand ==
+
-
(PLACEHOLDER)
+
-
 
+
-
== Exogenous Ligand ==
+
-
<StructureSection load='4ryy' size='340' side='right' caption='(''R'')-emixustat bound in the active site of RPE65' scene=''>
+
-
=== (''R'')-Emixustat (ACU-4429) ===
+
-
 
+
-
(''R'')-emixustat (ACU-4429) is an investigational small molecule inhibitor of RPE65 first invented by a British-American chemist, Ian L. Scott. Formulated as an hydrochloride salt, (''R'')-emixustat hydrochloride is taken by mouth and functions as a visual cycle modulator (VCM) to reduce toxic retinal byproducts such as A2E.
+
-
 
+
-
In 2008, Acucela Inc. partnered with Otsuka Pharmaceutical Company for the continued development of (''R'')-emixustat as a potential inhibitor of RPE65. Currently (''R'')-emixustat is in Phase III clinical trials in the United States for the potential treatment of Stargard's disease, a juvenile form of atrophic (dry) age dependent macular degeneration (AMD). Additionally, (''R'')-emixustat is investigated as potential therapy for diabetic retinopathy and diabetic macular edema.
+
-
 
+
-
</StructureSection>
+
-
 
+
-
<StructureSection load='4ryz' size='340' side='right' caption='(''S'')-emixustat bound in the active site of RPE65' scene=''>
+
-
=== (''S'')-Emixustat ===
+
-
(PLACEHOLDER)
+
-
 
+
-
</StructureSection>
+
-
 
+
-
== ''R/S'' Enantiomers Differences ==
+
-
(PLACEHOLDER)
+
-
 
+
-
= Disease Implications =
+
-
(PLACEHOLDER)
+
-
 
+
-
= Medical Relevance =
+
-
(PLACEHOLDER)
+
-
 
+
-
 
+
-
 
+
-
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
+
-
 
+
-
 
+
-
= References =
+
-
<references/>
+

Current revision

[[Media:RPE65_with_emixustat.mp4|PLACEHOLDER] width="576" height="324"] /Media:RPE65_with_emixustat.mp4


PLACEHOLDER


Media:RPE65_with_emixustat.mp4

Proteopedia Page Contributors and Editors (what is this?)

Ivan E. Wang

Retrieved from "http://52.214.119.220/wiki/index.php/User:Ivan_E._Wang/Sandbox_1"
Personal tools